<DOC>
	<DOCNO>NCT01573715</DOCNO>
	<brief_summary>Mortality Acute Respiratory Distress Syndrome high ( 40 60 % ) . Protective mechanical ventilation , 2010 , cornerstone ARDS therapeutic strategy . Recently , prospective multicenter study demonstrate 48h continuous infusion neuromuscular block agent ( NMBA ) positive impact mortality ARDS patient . ( Papazian et al . ACURASYS Study . NEJM 2010 ; 363:1107-16 ) . The mechanisms NMBAs could improve survival remain speculative . They follow : - reduction consumption oxygen link ventilatory workload ; - increase chest wall compliance improve mechanical ventilation ARDS good adaptation protective ventilation strategy ; - anti-inﬂammatory effect contribute reduction pulmonary inﬂammation improvement oxygenation , - reduction variation transpulmonary pressure ( TPP ) way good synchronisation patient ventilator . The use NMBA could also reduce ventilator induced lung injury well control TPP .</brief_summary>
	<brief_title>Effects Neuromuscular Blocking Agents ( NMBA ) Alteration Transpulmonary Pressures Early Phase Acute Respiratory Distress Syndrome ( ARDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Neuromuscular Blocking Agents</mesh_term>
	<mesh_term>Cisatracurium</mesh_term>
	<criteria>Early ( &lt; 48H ) Severe ARDS : PaO2 / FiO2 ratio &lt; 150 PEEP &gt; = 5 cmH20 Age &lt; 18 an Patient already continuous infusion NMBA . Known NMBA Allergy intolerance Contraindication introduction nasogastric tube</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>